News

August 31, 2017August 31, 2017

EU Approves Imraldi, a Biosimilar of Humira, for JA and Other Conditions

News

Imraldi, an adalimumab biosimilar referencing Abbvie’s Humira, has been approved by the European Commission, which means it can now be marketed in the European Union’s 28 member countries. Imraldi was developed ... Read more

August 29, 2017August 29, 2017

Biosimilar Erelzi Approved in Canada for Juvenile Arthritis, Other Inflammatory Diseases

News

Health Canada recently approved Erelzi, a biosimilar of Enbrel (etanercept), to treat juvenile idiopathic arthritis (JIA) and other chronic inflammatory diseases. Erelzi was developed by Sandoz, a subsidiary of the ... Read more

August 25, 2017August 25, 2017

Breastfeeding for Longer Than Four Months Reduces Risk of JIA in Children, Study Suggests

News

Breastfeeding for more than four months may reduce the risk of juvenile idiopathic arthritis (JIA) in children, according to a new study. The study, titled “Early feeding and risk of ... Read more

August 23, 2017August 23, 2017

Europe’s CHMP Green-lights AbbVie’s Humira for Pediatric Anterior Uveitis

News

The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion to Abbvie‘s Humira (adalimumab) for the treatment of chronic ... Read more

July 24, 2017July 24, 2017

Regulatory T-cell Levels Could Be Used to Diagnose Juvenile Arthritis, Study Reports

News

Patients with juvenile idiopathic arthritis have a lot of regulatory T-cells in their blood, particularly during active stages of the disease, a study indicates. The findings could lead to the ... Read more

July 20, 2017July 20, 2017

EU Commission Approves Biosimilar Erelzi to Treat Juvenile Arthritis, Other Chronic Inflammatory Diseases

News

The European Commission has approved the use of Erelzi – a biosimilar to Enbrel (etanercept) – to treat juvenile arthritis and several other chronic inflammatory diseases. Erelzi is produced by ... Read more

July 19, 2017July 19, 2017

Imraldi, Candidate for Humira Biosimilar, Is Step Closer to Approval in Europe

News

Samsung Bioepis received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on its marketing application for Imraldi, a Humira (adalimumab) ... Read more

July 17, 2017July 17, 2017

Arthritis National Research Foundation Earns Perfect Score from Charity Navigator

News

The Arthritis National Research Foundation (ANRF) has earned a perfect classification from the online Charity Navigator, with a score of 100 percent for fiscal management and accountability. This is ANRF’s ... Read more

July 13, 2017July 13, 2017

Rheumatologists, Surgeons Team Up on Guidelines to Prevent Joint Replacement Infections

News

Top American rheumatologists and orthopedic surgeons have collaborated for the first time to on guidelines aimed at reducing the risk of joint infection when a juvenile arthritis patient has to have ... Read more

July 11, 2017July 11, 2017

BMS Releases New Prefilled Injections of Orencia for Juvenile Idiopathic Arthritis Patients

News

Bristol-Myers Squibb recently announced that a new U.S. Food and Drug Administration (FDA)-approved formulation of Orencia (abatacept) is now available for patients with moderate to severely active polyarticular juvenile idiopathic arthritis. ... Read more